Emcure Pharmaceuticals Ltd

{"amount":3}

{"actualRevenue":24697030000,"estimateRevenue":24280000000,"revenueSurprise":417030000,"revenueSurprisePercent":1.717586490939044,"actualEPS":12.3,"estimateEPS":12.625,"surprise":-0.3249999999999993,"surprisePercent":-2.574257425742569}

{"actualRevenue":22698220000,"estimateRevenue":22614000000,"revenueSurprise":84220000,"revenueSurprisePercent":0.3724241620235252,"actualEPS":12.85,"estimateEPS":12.12,"surprise":0.7299999999999986,"surprisePercent":6.023102310231011}

{"actualRevenue":23634780000,"estimateRevenue":22288000000,"revenueSurprise":1346780000,"revenueSurprisePercent":6.042623833452979,"actualEPS":14.17,"estimateEPS":10.908,"surprise":3.261999999999999,"surprisePercent":29.90465713237989}

{"description":"Emcure Pharmaceuticals shares listed on NSE and BSE with a 31% premium to the IPO price, marking a strong market debut for the drugmaker.","url":"https://www.zeebiz.com/markets/ipo/news-emcure-pharmaceuticals-ipo-listing-price-bain-capital-backed-listing-price-nse-bse-ipo-price-rs-1008-300690","sentiment":"Positive","domain":"Zee Business"}

{"description":"Emcure Pharmaceuticals' consolidated net profit rose 28.81% in the March 2026 quarter; full-year profit climbed 35.67% to Rs 924.36 crore and sales increased 16.56% to Rs 9,203.54 crore.","url":"https://www.business-standard.com/markets/capital-market-news/emcure-pharmaceuticals-consolidated-net-profit-rises-28-81-in-the-march-2026-quarter-126050500853_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Emcure Pharmaceuticals Ltd received a 'No Action Indicated' classification from the FDA for its Gujarat manufacturing facility after an inspection from October 6-10, 2025. The company also launched Poviztra, a semaglutide injection for weight management, boosting shares by 3.40% to ₹1,426 on December 23, 2025.","url":"https://www.cnbctv18.com/market/emcure-pharma-share-price-us-fda-all-clear-for-gujarat-facility-obesity-drug-ws-l-19800870.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Emcure Pharmaceuticals shares surged 8% following a partnership with Novo Nordisk to launch Poviztra®, a weight-loss drug in India, making Emcure the first Indian firm to commercialize semaglutide. This collaboration aims to enhance access to obesity treatment in the country.","url":"https://www.cnbctv18.com/market/emcure-pharma-share-price-novo-nordisk-tie-up-to-launch-weight-loss-drug-poviztra-in-india-19751053.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Bain Capital-backed BC Investments IV is reportedly selling a 2.4% stake in Emcure Pharmaceuticals for Rs 551 crore via a block deal, totaling shares worth Rs 574 crore changing hands.","url":"https://www.moneycontrol.com/news/business/markets/emcure-pharmaceuticals-shares-in-focus-as-bain-capital-may-sell-2-4-stake-via-block-deals-13228724.html","sentiment":"Neutral","domain":"Moneycontrol"}

{"description":"Bain Capital sold a 2.4% stake in Emcure Pharmaceuticals for Rs 563 crore, decreasing its holding to 6.31%. Following the sale, Emcure Pharma's share price experienced a decline.","url":"https://money.rediff.com/news/market/bain-capital-sells-emcure-pharma-stake/29623720250704","sentiment":"Negative","domain":"Rediff Money"}